RTP Mobile Logo
The Practical Application of Research Advances and Emerging Data in the Management of Breast Cancer (Video Program)
Released April 2016

Proceedings from a satellite symposium during the 38th annual San Antonio Breast Cancer Symposium. Including perspectives from Drs Kimberly L Blackwell, Harold J Burstein, Lisa A Carey, Luca Gianni and Clifford Hudis. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer (BC).

    OVERVIEW OF ACTIVITY
    BC remains the most frequently diagnosed cancer in women, and in 2015 it is estimated that the disease culminated in 234,190 new cases and 40,730 deaths in the United States alone. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with BC has increased substantially, as has the population “at risk” for recurrent disease.

    The current clinical management of BC is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these approaches. The indication and/or utility of these local and systemic treatment options is largely based on a number of prognostic and predictive risk factors present within the patient or her tumor at the time of diagnosis. In fact, as the field of oncology is challenged to improve the precision with which it therapeutically targets malignant cells, biomarker-driven treatment algorithms have become the “norm” for many tumor types, particularly BC.

    These proceedings from a CME symposium during the 38th annual San Antonio Breast Cancer Symposium explore the most significant therapeutic advances during the previous year by using the perspectives of leading BC experts on challenging cases and questions submitted by clinicians in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help medical oncologists integrate these findings into best-practice disease management strategies.

    LEARNING OBJECTIVES
    • Appreciate the similarities and differences between existing genomic assays, and use this information to select an appropriate platform or platforms to assess risk and individualize therapy for patients with invasive early BC.
    • Individualize the selection of evidence-based neoadjuvant and adjuvant chemobiologic regimens for patients with HER2-overexpressing early BC.
    • Implement a long-term clinical plan for the management of metastatic HER2-positive BC, incorporating existing, recently approved and investigational targeted treatments.
    • Apply the results of emerging research to the initial and long-term care of localized, hormone receptor-positive pre- and postmenopausal BC.
    • Develop an evidence-based algorithm for the treatment of hormone-sensitive advanced BC, including the use of endocrine, biologic and chemotherapeutic agents.
    • Recognize the recent FDA approval of palbociclib for patients with ER-positive metastatic BC (mBC), and discern how this agent can be optimally integrated into clinical practice.
    • Consider clinical data and patient preferences in the selection and sequencing of available therapeutic agents for patients with ER/PR-negative, HER2-negative mBC, including the option of clinical trial participation.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in patients with mBC.
    • Counsel appropriately selected patients with BC about participation in ongoing clinical trials investigating novel therapeutic agents and strategies.
    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kimberly L Blackwell, MD

    Professor of Medicine
    Director, Breast Cancer Program
    Duke Cancer Institute
    Durham, North Carolina

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sandoz; Contracted Research: Celgene Corporation, Genentech BioOncology, Pfizer Inc.

    Harold J Burstein, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Lisa A Carey, MD
    Jacobs Preyer Distinguished Professor for Breast Cancer Research
    Chief, Division of Hematology and Oncology
    University of North Carolina
    Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina

    No relevant conflicts of interest to disclose.

    Luca Gianni, MD

    Director, Department of Medical Oncology
    Ospedale San Raffaele
    Scientific Institute
    Milan, Italy

    Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc.

    Clifford Hudis, MD
    Chief, Breast Medicine Service
    Solid Tumor Division
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Advisory Committee: Genentech BioOncology.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Alan B Astrow, MD
    Director, Hematology/Medical Oncology
    Maimonides Cancer Center
    Brooklyn, New York

    No relevant conflicts of interest to disclose.

    Patricia A DeFusco, MD
    Clinical Assistant Professor of Medicine
    University of Connecticut School of Medicine
    Director, Hartford Hospital Breast Program
    Physician Leader
    Hartford Healthcare Cancer Institute Breast Disease Management Team
    Hartford, Connecticut

    No relevant conflicts of interest to disclose.

    Bonni L Guerin, MD
    Director of Breast Cancer Treatment and Prevention
    Overlook Medical Center
    Summit, New Jersey

    No relevant conflicts of interest to disclose.

    Carolyn B Hendricks, MD
    Maryland Oncology Hematology
    Bethesda, Maryland

    No relevant conflicts of interest to disclose.

    Andrea Stebel, MD
    Newport Breast Care
    Newport Beach, California

    Speakers Bureau: Celgene Corporation.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Celgene Corporation, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Lilly and Myriad Genetic Laboratories Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date
    : April 2017

Acknowledge and close

View video: